Novavax Inc (NASDAQ:NVAX)
| 5.65 BATS BZX Real-Time Price As of 3:18pm ET |  -0.105 / -1.83%Today’s Change | 5.30 Today|||52-Week Range 18.55 | -45.09% Year-to-Date |
Latest NVAX News | Press Releases
| Is Novavax Stock a Buy Now? Dec 01 / MotleyFool.com - Paid Partner Content | Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use Nov 29 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 5.75 |
| Today’s open | 5.81 |
| Day’s range | 5.63 - 6.05 |
| Volume | 221,844 |
| Average volume (3 months) | 8,839,771 |
| Market cap | $657.5M |
Data as of 3:18pm ET, 12/05/2023
Growth & Valuation
| Earnings growth (last year) | +64.09% |
| Earnings growth (this year) | +74.87% |
| Earnings growth (next 5 years) | +45.10% |
| Revenue growth (last year) | +72.89% |
| P/E ratio | NM |
| Price/Sales | 0.41 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MLLCFMolecular Partners A... | 0.00 | 0.00% |
| KZRKezar Life Sciences ... | -0.00 | -0.36% |
| AUTLAutolus Therapeutics... | +0.13 | +3.33% |
| AVROAVROBIO Inc | +0.04 | +3.41% |
Data as of 3:19pm ET, 12/05/2023
Financials
| Next reporting date | February 27, 2024 |
| EPS forecast (this quarter) | $2.56 |
| Annual revenue (last year) | $2.0B |
| Annual profit (last year) | -$657.9M |
| Net profit margin | -33.20% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Gaithersburg, Maryland |
Forecasts
